$7.93
4.69% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Fennec Pharmaceuticals Inc. Stock price

$7.93
+1.45 22.38% 1M
+1.88 31.07% 6M
+1.61 25.47% YTD
+1.05 15.26% 1Y
-0.90 10.14% 5Y
+5.67 250.89% 10Y
-57.77 87.93% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.39 4.69%
ISIN
CA31447P1009
Symbol
FENC
Sector
Industry

Key metrics

Market capitalization $229.79m
Enterprise Value $225.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.29
P/S ratio (TTM) P/S ratio 7.43
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -31.25%
Revenue (TTM) Revenue $30.91m
EBIT (operating result TTM) EBIT $-11.98m
Free Cash Flow (TTM) Free Cash Flow $-16.39m
Cash position $22.68m
EPS (TTM) EPS $-0.53
P/E forward 49.52
P/S forward 4.96
EV/Sales forward 4.86
Short interest 7.47%
Show more

Is Fennec Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Fennec Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Fennec Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Fennec Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
31% 31%
100%
- Direct Costs 3.01 3.01
75% 75%
10%
28 28
35% 35%
90%
- Selling and Administrative Expenses 39 39
7% 7%
128%
- Research and Development Expense 0.40 0.40
567% 567%
1%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
292% 292%
-39%
Net Profit -14 -14
607% 607%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Fennec Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fennec Pharmaceuticals Inc. Stock News

Neutral
GlobeNewsWire
10 days ago
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
Neutral
Seeking Alpha
about one month ago
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer and Director Conference Call Participants Chase Knickerbocker - Craig Hallum Sudan Loganathan - Stevens Michael Okunewitch - Maxim Group Raghuram Selvaraju - H.C. Wainwright Operator Good morning,...
Neutral
GlobeNewsWire
about one month ago
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to di...
More Fennec Pharmaceuticals Inc. News

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Head office Canada
CEO Jeffrey Hackman
Employees 32
Founded 1996
Website fennecpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today